Heike Zeitler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Heike Zeitler has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Georg Goldmann
Institute of Experimental Haematology and Transfusion Medicine University Clinic Centre Bonn Bonn Germany
5 shared publicationsGudrun Ulrich-Merzenich
Internal Medical Clinic I, Center of Extracorporeal Therapy and Autoimmunity (CETA), Germany
5 shared publicationsG. Goldmann
Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Germany
4 shared publicationsHans Vetter
University of Bonn
4 shared publicationsJohannes Oldenburg
Institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Germany
4 shared publicationsPeter Walger
University of Bonn
4 shared publications
Latest Publications
- 1 May 2015
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 18, 74-79
Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?
- 1 May 2015
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 18, 74-79
Treatment of minor severe acquired haemophilia. Is there a rationale for immunoadsorption?
- 7 April 2015
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 19 (4) , 405-410
Extracorporeal Treatment in Severe Hypertriglyceridemia‐Induced Pancreatitis
Plasmapheresis is a well‐accepted treatment option in severe hypertriglyceridemia‐induced pancreatitis (HTGP). The rationale behind this approach is the depletion of triglycerides and the reduction of inflammatory cytokines. The time span between onset of clinical symptoms and start of plasmapheresis might have an important impact on mortality. Hyperviscosity of patients' plasma represents another special challenge for the applied separation technology. The procedures can be performed either by centrifugal device (CFD) or membrane based (MBS) units. The present study reports the outcome of 10 patients suffering from HTG. The expected mortality of the collective was 25%. Plasmapheresis was started after an average 16.3 h (SD ± 6.7 h) after onset of symptoms. No mortality occurred. Apheresis was statistically equally effective with both devices. A median of 3 sessions reduced the TG level to normal and correlated with patients' improvement. During follow up, three patients developed a pancreatic pseudocyst requiring surgical intervention without further complication.
- 7 April 2015
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 19 (4) , 405-410
Extracorporeal Treatment in Severe Hypertriglyceridemia‐Induced Pancreatitis
Plasmapheresis is a well‐accepted treatment option in severe hypertriglyceridemia‐induced pancreatitis (HTGP). The rationale behind this approach is the depletion of triglycerides and the reduction of inflammatory cytokines. The time span between onset of clinical symptoms and start of plasmapheresis might have an important impact on mortality. Hyperviscosity of patients' plasma represents another special challenge for the applied separation technology. The procedures can be performed either by centrifugal device (CFD) or membrane based (MBS) units. The present study reports the outcome of 10 patients suffering from HTG. The expected mortality of the collective was 25%. Plasmapheresis was started after an average 16.3 h (SD ± 6.7 h) after onset of symptoms. No mortality occurred. Apheresis was statistically equally effective with both devices. A median of 3 sessions reduced the TG level to normal and correlated with patients' improvement. During follow up, three patients developed a pancreatic pseudocyst requiring surgical intervention without further complication.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 35 (02) , 175-180
Long-term outcome of liver transplantation in HCV/HIV coinfected haemophilia patients
Summary: The outcome and clinical features during long term follow-up of 10 haemophilia patients (haemophilia A n = 9, haemophilia B n = 1), who underwent successful orthotopic liver transplantation (OLT) due to hepatitis associated liver disease, are summarised.Eight patients were HIV/HCV co-infected. Despite severe postoperative complications, which were not bleeding-associated, all patients survived OLT.Long-term survival was 70% after in mean 8 years follow- up. Twelve years after OLT one patient developed a cyclosporine-induced nephropathy requiring haemodialysis. HIV-HAART was initiated in all patients after OLT, and allowed a successful HCV treatment in 6 patients. Factor VIII production was sufficient in mean 72 h after OLT and remained stable at subnormal to normal FVIII levels of in median 30% (range 14–96%) also during long-term follow-up. Post-OLT spontaneous bleeding events were rare compared to pre-OLT, therefore, the performance status improved in all patients.OLT substitutes the hepatic FVIII but has no effect on the extrahepatic endothelial FVIII production, suggesting that in case of severe tissue injury enhanced bleeding might occur. Additionally, after OLT there is no acute phase reaction of the FVIII protein. Therefore, our OLT patients received in case of a reduced FVIII activity a peri-interventional prophylactic short-term FVIII substitution in surgical and diagnostic interventions with high bleeding risk.Bleeding and wound healing disturbances were not seen.
- 1 January 2015
- Published by Georg Thieme Verlag KG in Hamostaseologie
- Vol. 35 (02) , 175-180
Long-term outcome of liver transplantation in HCV/HIV coinfected haemophilia patients
Summary: The outcome and clinical features during long term follow-up of 10 haemophilia patients (haemophilia A n = 9, haemophilia B n = 1), who underwent successful orthotopic liver transplantation (OLT) due to hepatitis associated liver disease, are summarised.Eight patients were HIV/HCV co-infected. Despite severe postoperative complications, which were not bleeding-associated, all patients survived OLT.Long-term survival was 70% after in mean 8 years follow- up. Twelve years after OLT one patient developed a cyclosporine-induced nephropathy requiring haemodialysis. HIV-HAART was initiated in all patients after OLT, and allowed a successful HCV treatment in 6 patients. Factor VIII production was sufficient in mean 72 h after OLT and remained stable at subnormal to normal FVIII levels of in median 30% (range 14–96%) also during long-term follow-up. Post-OLT spontaneous bleeding events were rare compared to pre-OLT, therefore, the performance status improved in all patients.OLT substitutes the hepatic FVIII but has no effect on the extrahepatic endothelial FVIII production, suggesting that in case of severe tissue injury enhanced bleeding might occur. Additionally, after OLT there is no acute phase reaction of the FVIII protein. Therefore, our OLT patients received in case of a reduced FVIII activity a peri-interventional prophylactic short-term FVIII substitution in surgical and diagnostic interventions with high bleeding risk.Bleeding and wound healing disturbances were not seen.
- 4 July 2013
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 18 (1) , 103-110
Immunoadsorption for Pregnancy‐Associated Severe Acquired Hemophilia
Postpartum hemorrhage is a common cause of maternal mortality. Acquired hemophilia (AH) is a rare, life‐threatening bleeding disorder induced by autoantibodies against coagulation factors (inhibitors). We report about eight patients with postpartum AH (out of 82). Seven AH patients with severe bleeding complications were treated by the “Modified Bonn‐Malmö Protocol (MBMP)” which consists of inhibitor elimination via immunoadsorption (IA) in combination with immunosuppression and high‐dose Factor VIII substitution. One patient was treated only by immunosuppression. Seven out of eight patients with severe AH and mean inhibitor titers (IT) of 118 BU/mL were referred to our center. They were severe cases with a median delay of diagnosis of 30.5 days (range 7–278 days). After a median of 3 IA sessions (range 3–5 days), no inhibitor was detectable. The factor substitution was discontinued after a median of 13 IA sessions (range 8–24 days) and IA was terminated after a median of 15 sessions (range 9–27 days). One less severe affected patient (IT: 2.1 BU/mL) received prednisolone (1.5 mg/kg BW) for 120 days. Complete remission was achieved in all patients with a median follow‐up of 100 months (range 56–126 m). The delayed diagnosis of pregnancy‐associated AH leads to a high bleeding risk with bleeding associated complications. Immunoadsorption offers an important treatment option in severe AH, enabling a fast reconstitution of the blood coagulation with a reduced time for the Factor VIII substitution and for immunosuppressive treatment. In cases of postpartum bleeding the diagnosis of AH should be routinely considered.
- 4 July 2013
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 18 (1) , 103-110
Immunoadsorption for Pregnancy‐Associated Severe Acquired Hemophilia
Postpartum hemorrhage is a common cause of maternal mortality. Acquired hemophilia (AH) is a rare, life‐threatening bleeding disorder induced by autoantibodies against coagulation factors (inhibitors). We report about eight patients with postpartum AH (out of 82). Seven AH patients with severe bleeding complications were treated by the “Modified Bonn‐Malmö Protocol (MBMP)” which consists of inhibitor elimination via immunoadsorption (IA) in combination with immunosuppression and high‐dose Factor VIII substitution. One patient was treated only by immunosuppression. Seven out of eight patients with severe AH and mean inhibitor titers (IT) of 118 BU/mL were referred to our center. They were severe cases with a median delay of diagnosis of 30.5 days (range 7–278 days). After a median of 3 IA sessions (range 3–5 days), no inhibitor was detectable. The factor substitution was discontinued after a median of 13 IA sessions (range 8–24 days) and IA was terminated after a median of 15 sessions (range 9–27 days). One less severe affected patient (IT: 2.1 BU/mL) received prednisolone (1.5 mg/kg BW) for 120 days. Complete remission was achieved in all patients with a median follow‐up of 100 months (range 56–126 m). The delayed diagnosis of pregnancy‐associated AH leads to a high bleeding risk with bleeding associated complications. Immunoadsorption offers an important treatment option in severe AH, enabling a fast reconstitution of the blood coagulation with a reduced time for the Factor VIII substitution and for immunosuppressive treatment. In cases of postpartum bleeding the diagnosis of AH should be routinely considered.
- 26 January 2013
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 14 (1) , 223-228
Long term outcome of patients with acquired haemophilia – A monocentre interim analysis of 82 patients
- 26 January 2013
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 14 (1) , 223-228
Long term outcome of patients with acquired haemophilia – A monocentre interim analysis of 82 patients
- 1 January 2012
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 39 (4) , 264-270
Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia
Objectives: In acquired hemophilia (AH), autoantibodies (inhibitors) impede blood coagulation factors leading to severe bleedings. Cornerstones of a successful treatment are the control of bleeding and an eradication of autoantibodies. The present study is an update of our previous documentation of the treatment of high-titer AH patients with severe life-threatening bleeding undergoing the modified Bonn-Malmö-Protocol (MBMP). Methods: 64 AH patients were treated by a standard combination protocol (MBMP) consisting of antibody depletion through immunoadsorption, i.v. immunoglobulin, immunosuppression, and high-dose FVIII substitution. They underwent a long-term follow-up. Results: Primary study endpoints loss of detection of the activity of the inhibitor and FVIII recovery ≥ 5% were reached in a median time of 3 days (95% CI: 2.6–3.4 days), the median time of FVIII substitution was 13 days (95% CI 10.6–15.3 days), and the median time of immunoadsorption was 16 days (95% CI 13–18.9 days). In 5 patients the AH occurred as paraneoplastic syndrome, and partial remission was achieved. Relapses without bleeding event occurred only in second-line MBMP. Those responded excellently to short time treatment. Overall patients remained in remission over a median follow-up time of 8 years. Conclusion: Except for paraneoplastic AH, MBMP-treated patients have a remarkable prognosis which is confirmed by long-term follow-up with a complete response rate of 93% (53/57) in the first year post MBMP and 100% during long-term follow-up. These outcome in life-threatening AH is unique and until now not achievable via other treatment schedules. In life-threatening bleedings physicians should take into account MBMP as a first line treatment.
- 1 January 2012
- Published by S. Karger AG in Transfusion Medicine and Hemotherapy
- Vol. 39 (4) , 264-270
Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia
Objectives: In acquired hemophilia (AH), autoantibodies (inhibitors) impede blood coagulation factors leading to severe bleedings. Cornerstones of a successful treatment are the control of bleeding and an eradication of autoantibodies. The present study is an update of our previous documentation of the treatment of high-titer AH patients with severe life-threatening bleeding undergoing the modified Bonn-Malmö-Protocol (MBMP). Methods: 64 AH patients were treated by a standard combination protocol (MBMP) consisting of antibody depletion through immunoadsorption, i.v. immunoglobulin, immunosuppression, and high-dose FVIII substitution. They underwent a long-term follow-up. Results: Primary study endpoints loss of detection of the activity of the inhibitor and FVIII recovery ≥ 5% were reached in a median time of 3 days (95% CI: 2.6–3.4 days), the median time of FVIII substitution was 13 days (95% CI 10.6–15.3 days), and the median time of immunoadsorption was 16 days (95% CI 13–18.9 days). In 5 patients the AH occurred as paraneoplastic syndrome, and partial remission was achieved. Relapses without bleeding event occurred only in second-line MBMP. Those responded excellently to short time treatment. Overall patients remained in remission over a median follow-up time of 8 years. Conclusion: Except for paraneoplastic AH, MBMP-treated patients have a remarkable prognosis which is confirmed by long-term follow-up with a complete response rate of 93% (53/57) in the first year post MBMP and 100% during long-term follow-up. These outcome in life-threatening AH is unique and until now not achievable via other treatment schedules. In life-threatening bleedings physicians should take into account MBMP as a first line treatment.
- 23 April 2010
- Published by Wiley in Haemophilia
- Vol. 16 (102) , 95-101
The relevance of the bleeding severity in the treatment of acquired haemophilia – an update of a single‐centre experience with 67 patients
Summary. Acquired haemophilia (AH), an autoimmune disorder with clinical features ranging from harmless haematomas to life‐threatening bleedings, still has a mortality rate of up to 25%. Owing to its low frequency (1–4 × 106), standardized treatment protocols for its variable manifestations are not available. In case of prominent severe bleedings, the treatment should aim at rapid elimination of the antibody to protect patients from bleedings and on reinduction of long‐term immune tolerance. Clinical data, short‐ and long‐term treatment results of 67 patients diagnosed by our centre are presented. Patients were treated depending on their bleeding severity either by an immunosuppressive treatment alone, or in case of life‐threatening bleedings, by a combined protocol (modified Bonn–Malmö protocol, MBMP) consisting of antibody depletion through immunoadsorption, intravenous immunoglobulin treatment, immunosuppression and high‐dose factor VIII (FVIII) substitution. Mild bleedings occurred in two patients who were treated successfully alone by immunosuppression. Complete remission (CR) was achieved in 90% of the patients treated with MBMP (60). Of the six patients (10%) who achieved a partial remission (PR), four suffered from cancer. Mortality under MBMP was not seen. In contrast, five patients, in whom diagnosis of AH was delayed, experienced fatal outcome during surgical interventions before initiation of MBMP treatment. Prognosis in AH depends mainly on its prompt diagnosis. Treatment procedures should be adapted to bleeding severity and inhibitor titres. Under these conditions, AH is a potentially curable autoimmune disorder with an excellent prognosis.
- 23 April 2010
- Published by Wiley in Haemophilia
- Vol. 16 (102) , 95-101
The relevance of the bleeding severity in the treatment of acquired haemophilia – an update of a single‐centre experience with 67 patients
Summary. Acquired haemophilia (AH), an autoimmune disorder with clinical features ranging from harmless haematomas to life‐threatening bleedings, still has a mortality rate of up to 25%. Owing to its low frequency (1–4 × 106), standardized treatment protocols for its variable manifestations are not available. In case of prominent severe bleedings, the treatment should aim at rapid elimination of the antibody to protect patients from bleedings and on reinduction of long‐term immune tolerance. Clinical data, short‐ and long‐term treatment results of 67 patients diagnosed by our centre are presented. Patients were treated depending on their bleeding severity either by an immunosuppressive treatment alone, or in case of life‐threatening bleedings, by a combined protocol (modified Bonn–Malmö protocol, MBMP) consisting of antibody depletion through immunoadsorption, intravenous immunoglobulin treatment, immunosuppression and high‐dose factor VIII (FVIII) substitution. Mild bleedings occurred in two patients who were treated successfully alone by immunosuppression. Complete remission (CR) was achieved in 90% of the patients treated with MBMP (60). Of the six patients (10%) who achieved a partial remission (PR), four suffered from cancer. Mortality under MBMP was not seen. In contrast, five patients, in whom diagnosis of AH was delayed, experienced fatal outcome during surgical interventions before initiation of MBMP treatment. Prognosis in AH depends mainly on its prompt diagnosis. Treatment procedures should be adapted to bleeding severity and inhibitor titres. Under these conditions, AH is a potentially curable autoimmune disorder with an excellent prognosis.
- 1 December 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (5) , 122-125
Immunoadsorption in the treatment of Acquired Haemophilia
- 1 December 2009
- Published by Elsevier in Atherosclerosis Supplements
- Vol. 10 (5) , 122-125
Immunoadsorption in the treatment of Acquired Haemophilia
- 5 June 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 18 (10) , 1354-1356
Multiple Benign Symmetric Lipomatosis—A Differential Diagnosis of Obesity. Is There a Rationale for Fibrate Treatment?
Multiple benign symmetric lipomatosis (MSL) is characterized by a rapid progression of multiple, symmetric nonencapsulated fat masses in the face, neck, and extremities. The lipomas are thought to be the result of defective brown adipose tissue (BAT). In up to 90% MSL is associated with chronic alcohol abuse. Prognosis depends on the concomitant presence of a neuropathy with a mortality of 25.8%. Therapeutic options are limited to alcohol abstinence and surgical interventions. We report here about a 53-year-old MSL patient who increased his body weight by 37 kg over 10 years. Multiple lipectomies were performed, but disease progressed. We treated him with fenofibrates (200 mg/day). Disease progression discontinued and circumferences of abdominal adipose tissue reduced. Fibrates, peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, are pleiotropic hypolipidemic drugs, and might have worked by suppression of protein expressions involved in the architecture of BAT keeping it in a quiescent state.
- 5 June 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 18 (10) , 1354-1356
Multiple Benign Symmetric Lipomatosis—A Differential Diagnosis of Obesity. Is There a Rationale for Fibrate Treatment?
Multiple benign symmetric lipomatosis (MSL) is characterized by a rapid progression of multiple, symmetric nonencapsulated fat masses in the face, neck, and extremities. The lipomas are thought to be the result of defective brown adipose tissue (BAT). In up to 90% MSL is associated with chronic alcohol abuse. Prognosis depends on the concomitant presence of a neuropathy with a mortality of 25.8%. Therapeutic options are limited to alcohol abstinence and surgical interventions. We report here about a 53-year-old MSL patient who increased his body weight by 37 kg over 10 years. Multiple lipectomies were performed, but disease progressed. We treated him with fenofibrates (200 mg/day). Disease progression discontinued and circumferences of abdominal adipose tissue reduced. Fibrates, peroxisome proliferator-activated receptor alpha (PPAR alpha) agonists, are pleiotropic hypolipidemic drugs, and might have worked by suppression of protein expressions involved in the architecture of BAT keeping it in a quiescent state.
- 4 January 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 18 (2) , 240-242
Multiple Benign Symmetric Lipomatosis—A DifferentialDiagnosis of Obesity
Multiple benign symmetric lipomatosis (MSL) is characterized by a rapid progression of multiple, symmetric nonencapsulated fat masses in face, neck, and extremities. The lipomas are thought to be the result of defective brown adipose tissue (BAT). In up to 90%, MSL is associated with chronic alcohol abuse. Prognosis depends on the concomitant presence of a neuropathy with a mortality of 25.8%. Therapeutic options are limited to alcohol abstinence and surgical interventions. We report here about a 53-year-old MSL patient who increased his body weight by 37 kg over 10 years. Multiple lipectomies were performed but disease progressed. We treated him with fenofibrates (200 mg/day). Disease progression discontinued, and circumferences of abdominal adipose tissue reduced. Fibrates, peroxisome proliferator-activated receptor alpha agonists, are pleiotropic hypolipidemic drugs and might have worked by suppression of protein expressions involved in the architecture of BAT keeping it in a quiescent state.
- 4 January 2008
- Published by Springer Nature in Obesity Surgery
- Vol. 18 (2) , 240-242
Multiple Benign Symmetric Lipomatosis—A DifferentialDiagnosis of Obesity
Multiple benign symmetric lipomatosis (MSL) is characterized by a rapid progression of multiple, symmetric nonencapsulated fat masses in face, neck, and extremities. The lipomas are thought to be the result of defective brown adipose tissue (BAT). In up to 90%, MSL is associated with chronic alcohol abuse. Prognosis depends on the concomitant presence of a neuropathy with a mortality of 25.8%. Therapeutic options are limited to alcohol abstinence and surgical interventions. We report here about a 53-year-old MSL patient who increased his body weight by 37 kg over 10 years. Multiple lipectomies were performed but disease progressed. We treated him with fenofibrates (200 mg/day). Disease progression discontinued, and circumferences of abdominal adipose tissue reduced. Fibrates, peroxisome proliferator-activated receptor alpha agonists, are pleiotropic hypolipidemic drugs and might have worked by suppression of protein expressions involved in the architecture of BAT keeping it in a quiescent state.